Navigation Links
Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
Date:7/7/2010

=s_gi(s_account);s.linkTrackVars='prop5,eVar3,prop15';s.prop5='External Link';s.eVar3=s.prop5;s.prop15='97916434';s.tl(this,'o','ExternalLink');" target='_blank' href="http://www.silence-therapeutics.com/">www.silence-therapeutics.com)

Silence Therapeutics plc (AIM: SLN) is a leading global biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases.  The company possesses multiple proprietary short interfering RNA (siRNA) delivery technology platforms including AtuPLEX™, a system that enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake.  A second, complementary delivery technology known as PolyTran™ uses a library of novel peptide-based biodegradable polycationic polymers for systemic siRNA administration.  Additionally, the company has a platform of novel siRNA molecules, AtuRNAi, which provide a number of advantages over conventional siRNA molecules, including increased stability against nuclease degradation.  Silence's unique RNAi assets also include structural features for a next generation of RNAi molecules and additional proprietary siRNA sequences against more than 50 highly valued oncology and other disease targets.

The company's strong and diverse intellectual property portfolio includes exclusive licenses from the University of Massachusetts Medical School on three patent families associated with the Zamore "Design Rules," which cover broad structural features of siRNA design for more potent next generation siRNA sequences.

Silence Therapeutics is headquartered in London, UK, with research and development activities in

SOURCE Silence Therapeutics plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
2. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
3. Silence Therapeutics Announces Successful Opposition of Glover Patent
4. Organizational Changes at Silence Therapeutics
5. Silence Obtains Important Patent Protection for Lead Internal Development Compound, Atu027
6. Silence Therapeutics Patent Update
7. Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent
8. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
9. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
10. Silence Therapeutics Appoints New Vice President of Research
11. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Two champions of science, technology, engineering, ... an annual competition for middle and high school students ... STEM study. The competition presents students with real-world problems ... Aptitude, Mathematics, and Sciences is a program administered ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 Freeslate, ... solutions, today announced that Lupin Limited, one of India’s ... CM Protégé PharmD System for high throughput ... India, is focused on a wide range of quality, ...
(Date:1/14/2014)... Washington, DC (PRWEB) January 14, 2014 ... session for Thursday, January 23, 2014 at 2pm EST ... Actionable Knowledge.” The topic focuses on how technology can ... mission critical decisions for government agencies. The online webinar ...
(Date:1/14/2014)... 14, 2014 EquitiesIQ, a leading informational ... ALQA). Alliqua is an emerging biomedical company acquiring, developing, ... care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... seasoned management team and Board, which launched the company’s ...
Breaking Biology Technology:Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... ... Prize in Chemistry published papers on their award-winning work based on data collected at the ... ... Nobel Prize in Chemistry published papers on their award-winning work based on data collected at ...
... Inc. (Nasdaq: LXRX ) today announced that it ... conditions, 27,500,000 shares of its common stock pursuant to ... are being offered through the underwriters and 11,087,387 shares ... Lexicon also intends to grant the underwriters a ...
... ... President Obama , ... Argonne, Ill. (Vocus) October 7, 2009 -- The IBM Blue Gene series of energy-efficient ... President Barack Obama as a Medal of Technology and Innovation award-winner on October 7 ...
Cached Biology Technology:Argonne's Advanced Photon Source Lit the Way to Chemistry Nobel 2Argonne's Advanced Photon Source Lit the Way to Chemistry Nobel 3Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock 2Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock 3DOE Labs Take Pride in Award-Winning IBM Blue Gene Series 2DOE Labs Take Pride in Award-Winning IBM Blue Gene Series 3DOE Labs Take Pride in Award-Winning IBM Blue Gene Series 4
(Date:4/16/2014)... in museum collections two new species of yellow-shouldered bats have been ... The Field Museum of Natural History and described in the open ... to the genus Sturnira are part of a recent ... the third one still waiting to be officially announced. , Up ...
(Date:4/16/2014)... leaf looks like one seamless surface; however, up close, ... patchwork of cells in a variety of shapes and ... their own unique forms, Caltech biologist Elliot Meyerowitz, postdoctoral ... shape-controlling factors in pavement cells, which are puzzle-piece-shaped epithelial ...
(Date:4/16/2014)... , Professor Nicolas Doucet of the Centre INRSInstitut Armand-Frappier has ... Health (NIH) in the amount of nearly US$600,000. The 5-year ... tiny proteins called RNases and to explore their biomedical potential ... and asthma. , "Receiving a grant at this ...
Breaking Biology News(10 mins):Two new species of yellow-shouldered bats endemic to the Neotropics 2For cells, internal stress leads to unique shapes 2High-level NIH grant goes to professor Nicolas Doucet of INRS 2
... BEDFORD, Mass., July 16 Aware, Inc. (Nasdaq: ... scheduled a conference call to discuss the company,s operating results for the ... Time. CEO Michael Tzannes and CFO Rick Moberg will host the earnings ... being webcast by Thomson and can be accessed on the Investor Relations ...
... Blacksburg, Va. -- Ten articles describing how a universal ... study of the microbial world have been published in ... co-edited by Virginia Bioinformatics Institute professor Brett Tyler. The ... a shared vocabulary to describe disease-related and beneficial interactions ...
... early-life experience sticks with them into adulthood and may render ... aging, according to a new UBC study. A team ... genome-wide profiling in 103 healthy adults aged 25-40 years. ... high in early-life socioeconomic circumstances related to income, education and ...
Cached Biology News:Aware, Inc. Announces Q2'09 Earnings Conference Call 2Reviews of microbial gene language published in special issue of Trends in Microbiology 2Reviews of microbial gene language published in special issue of Trends in Microbiology 3Reviews of microbial gene language published in special issue of Trends in Microbiology 4Early-life experience linked to chronic diseases later in life: UBC research 2
Agarose II (Low Melt)...
...
... I can be used in intracellular staining ... cells and to serve as an antibody ... cell permeabilization is a reversible process, it ... the presence of saponin during intracellular staining. ...
... antibody raised against a partial ... Immunogen: PPP4C (NP_002711, 218 ... recombinant protein with GST tag. ... NM_002720 ...
Biology Products: